GO
Loading...

Eli Lilly and Co

More

  • *No EU concerns about Eli Lilly, Novartis deal. In contrast, U.S. drugmaker Eli Lilly's proposed $5.4 billion takeover of Swiss peer Novartis's animal health business triggered no such worries and will be cleared unconditionally, the sources said. Eli Lilly is buying the Novartis unit to strengthen and diversify its Elanco unit.

  • Eli Lilly to drop development of lupus drug Thursday, 2 Oct 2014 | 8:57 AM ET

    Oct 2- Eli Lilly and Co said it would discontinue the development of its lupus drug as the treatment was not found to be effective enough in two late-stage trials. The decision will result in a charge of about 4- 5 cents per share in the third quarter, the company said. Eli Lilly said the decision was not because of any safety concerns.

  • A blast from Martha's past: Waksal plans new IPO Wednesday, 24 Sep 2014 | 7:31 AM ET
    Former ImClone CEO Sam Waksal leaves federal court in New York, June 10, 2003.

    Banned ImClone founder Sam Waksal's new biotech company, Kadmon, has plans to go public. The company aims to file with the SEC by the end of this year.

  • Sept 17- Testosterone replacement therapies should be reserved for men with specific medical conditions that impair function of the testicles, an advisory panel to the U.S. Food and Drug Administration concluded on Wednesday. The FDA is not obliged to follow the advice of its advisory panels but typically does so.

  • For Roche CEO, celebrating failure is key to success Wednesday, 17 Sep 2014 | 8:06 AM ET

    LONDON, Sept 17- Roche Chief Executive Severin Schwan likes to crack open the champagne with his drug research teams at the end of a big project- especially when they fail.

  • NEW YORK, Sept 16- U.S. stocks were set to open lower on Tuesday with traders positioning for a Federal Reserve meeting expected to provide clues on the short term direction of U.S. interest rates.

  • Early movers: HSY, SHLD, BX, BA, LMNT, BABA & more Tuesday, 16 Sep 2014 | 7:35 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • US STOCKS-Futures dip ahead of data, Fed eyed Tuesday, 16 Sep 2014 | 7:33 AM ET

    *The Labor Department's producer price index, due at 8:30 a.m. EDT, is expected to have risen 0.1 percent in August, the same as in July.

  • *Lilly to partner on AstraZeneca's BACE inhibitor drug. LONDON, Sept 16- AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising- but risky- experimental Alzheimer's drug proves successful.

  • Midday movers: eBay, Sprint, Yahoo & more Friday, 12 Sep 2014 | 12:20 PM ET

    Take a look at some of Friday's midday movers:

  • Sept 12- Eli Lilly and Co's Cyramza stomach-cancer drug prolonged survival of patients with advanced colon cancer in a late-stage study, the U.S. drugmaker said on Friday. The 1,000- patient global study, called RAISE, involved patients who had previously failed to adequately benefit from Roche Holding AG's Avastin and other standard treatments.

  • Sept 10- Eli Lilly and Co and Boehringer Ingelheim said on Wednesday that the European Commission approved their copycat version of Sanofi SA's blockbuster insulin, Lantus. The therapy received a positive recommendation from the European Medicine Agency in June.

  • Can anything slow Gilead down? Analysts say no Monday, 8 Sep 2014 | 3:12 PM ET
    Darryl Kato, research scientist for Gilead Sciences, works on the synthesis of a potential hepatitis C virus drug candidate at the company's lab in Foster City, California, Feb. 8, 2012.

    Gilead is already among the 10 best performers in the Nasdaq 100 this year. So can anything slow this behemoth down? If you ask the analysts, it sounds unlikely.

  • Early movers: TIF, AAPL, T, AGN, PFE, TIVO & more Wednesday, 27 Aug 2014 | 8:13 AM ET
    Traders work on the floor of the New York Stock Exchange (NYSE) on Friday.

    Some of the names on the move ahead of the open.

  • Aug 21- An experimental new psoriasis treatment from Eli Lilly and Co proved superior to Amgen Inc's blockbuster Enbrel, drawing it closer to a potential marketing battle with new products being developed by Amgen and Novartis AG.

  • Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. The most common inflammatory disease in the United States- it can occur on any part of the body- it is associated with diabetes and heart disease.

  • Lilly psoriasis drug succeeds in late-stage studies Thursday, 21 Aug 2014 | 7:16 AM ET

    Aug 21- Eli Lilly and Co said its experimental psoriasis drug was found to be more effective in clearing skin than a generic treatment and a placebo in late-stage studies. Three studies evaluated the drug, ixekizumab, against the generic etanercept and a placebo, in patients with moderate-to-severe plaque psoriasis.

  • Early movers: HD, BHP, BAC, URBN, RDEN, LLY & more Tuesday, 19 Aug 2014 | 7:56 AM ET
    Traders work on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • SAN FRANCISCO, Aug 14- A group of ex-gaming industry executives say they can use their design chops to solve a major health challenge: Sick patients neglecting to take their medication and costing employers and insurance providers billions of dollars.

  • Aug 14- An Indianapolis church has alleged that JPMorgan Chase& Co mismanaged trust accounts held for its benefit by investing in high cost, risky investments that advanced the firms' interests over its own, according to a lawsuit filed in Indianapolis federal court late on Wednesday.